购物车0
产品总数：61470
| 中文名称 |
Terconazole
|
|---|---|
| 中文别名 |
特康唑;曲康唑;1-[4-[[(2R,4S)-2-(2,4-二氯苯基)-2-(1,2,4-三唑-1-基甲基)-1,3-二氧戊环-4-基]甲氧基]苯基]-4-丙-2-基哌嗪;曲康唑、特康唑;曲康唑 USP标准品;特康唑 EP标准品;特康唑 标准品;特康唑,曲康唑
|
| 英文名称 |
Terconazole
|
| 英文别名 |
Triaconazole;TERCONAZOLE;Terconagole;TERCONAZOLE EPT(CRM STANDARD);TERCONAZOLE USP(CRM STANDARD);1-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-yl-piperazine;Fungistat;R42470;(+-)-1-{4-[cis-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylmethoxy]phenyl}-4-isopropylpiperazine;Gyno-Terazol;Terazol 7;Terazol 3;Terazol;C26H31Cl2N5O3;Terconazol;Terconazolum;Zazole;Terazol 7 & 3;Terconazol [INN-Spanish];Terconazolum [INN-Latin];1-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-propan-2-ylpiperazine;Terazol Cream & Suppositories;R 42,470;Tercospor;Panlomyc;Terconazole [USAN:INN:BAN];cis-1-(p-((2-(2,4-Dich;Terconazole
|
| Cas No. |
67915-31-5
|
| 分子式 |
C26H31Cl2N5O3
|
| 分子量 |
532.46
|
| 包装储存 |
Powder -20°C 3 years；4°C 2 years
|
| 产品详情 |
Terconazole (R42470) 是用于研究阴道酵母菌感染的广谱抗真菌药物。
|
|---|---|
| 生物活性 |
Terconazole is a broad-spectrum antifungal medication for the treatment of vaginal yeast infection.
|
| 性状 |
Solid
|
| 体外研究(In Vitro) |
Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL. has not independently confirmed the accuracy of
|
| 体内研究(In Vivo) |
A 3-day once-daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years；4°C 2 years
|
| ClinicalTrial |
|
| 参考文献 |
[1]. Tolman EL, et al. Anticandidal activities of terconazole, a broad-spectrum antimycotic. Antimicrob Agents Chemother. 1986 Jun;29(6):986-91.[2]. Van Cutsem J, et al. The in vitro activity of terconazole against yeasts: its topical long-acting therapeutic efficacy in experimental vaginal candidiasis in rats. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1200-6.
|
| 溶解度数据 |
In Vitro: DMSO : ≥ 30 mg/mL (56.34 mM)配制储备液
|
|---|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
